Longevity protocol suppliers – whether offering nutraceutical stacks, lifestyle systems, or multi-step programmes – all face the same challenge: proving that their solution actually changes something meaningful in the body. mescreen™ provides an independent, third-party way to evaluate how a protocol affects mitochondrial efficiency, offering suppliers robust, cellular-level evidence to support their claims.

By integrating mescreen™ into your product or service roadmap, you can run structured before-and-after studies in real-world users. This allows you to see whether your protocol improves mitochondrial function over defined timeframes and in which subgroups it performs best. Those insights can refine your product design, positioning, and go-to-market strategies.

For customers, combining your protocol with optional mescreen™ testing creates a stronger value proposition: they are not just following steps; they can measure a deep, mechanistic outcome. This supports both B2B and B2C adoption, enabling you to partner with clinics, coaches, and wellness providers who want evidence-based tools.

Commercially, mescreen™ can be positioned as a validation layer and as an ongoing monitoring tool. It strengthens your differentiation against competitors with unsubstantiated or anecdotal claims and supports premium pricing, especially in sophisticated longevity markets.